John Maslowski

Chief Commercial Officer • Forge Biologics

Mr. Maslowski served as the President and Chief Executive Officer of Castle Creek Biosciences, Inc. from January 2020 to March 2021 and served in the same role at Fibrocell Science, Inc. (a NASDAQ rare disease cell and gene therapy company) from December 2016 until Fibrocell was acquired in December 2019. At Fibrocell, he previously served as the Senior Vice President of Scientific Affairs and Vice President of Operations of Fibrocell from 2012 to 2016. Mr. Maslowski has extensive experience in the field of cell and gene therapy, including advancing D-Fi, a genetically modified autologous fibroblast therapy, to pivotal clinical trials, and LAVIV ® , a non-modified autologous fibroblast therapy, through U.S. FDA approval and commercialization.

Mr. Maslowski also serves on the board of Alliance for Regenerative Medicine, an advocacy organization dedicated to developing and advancing advanced therapies, the scientific advisory board of Castle Creek Biosciences, and the advisory board of Life Science Cares Philadelphia, a charitable organization. Mr. Maslowski previously served as the Chairman of the board of directors of Falcon Therapeutics, a privately held Durham, N.C. company focused on the development of cell therapy products for oncology, from 2019 to 2021, and on the board of directors of Castle Creek Biosciences and Fibrocell from 2016 to 2021.

Prior to Fibrocell, Mr. Maslowski held positions at major pharmaceutical companies including Wyeth Pharmaceuticals, Merck & Co., Inc., and Teva Pharmaceuticals Industries Ltd, with 20+ years of experience in pharmaceutical and biologics development. Mr. Maslowski received his B.S. in biology from Ursinus College and his M.S. in microbiology from Villanova University.

Also Speaking

Barbara A. Binzak Blumenfeld

Shareholder, FDA & Biotechnology • Buchanan Ingersoll Rooney

Anthony Oliva

Senior Scientist • Longeveron

Will Chou

Chief Executive Officer • Aruvant

Event Info


Fun Run